Why Heron Therapeutics Stock Is Tanking Today
Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biopharma company, is having a tough go of it today. The company's shares were down by 28.6% as of 10:21 a.m. EDT on Monday.
The culprit? Ahead of the opening bell, Heron announced that the Food and Drug Administration rejected its non-opioid painkiller HTX-011. Heron stated that the drug's regulatory filing was declined because of four non-clinical issues.
Image source: Getty Images.
Source Fool.com
